Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 17 - Drugs for dermatological disorders
Patents for A61P 17 - Drugs for dermatological disorders (106,455)
05/2003
05/02/2003EP1305291A1 3-substituted isoquinolin-1-yl derivatives
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305274A2 Novel c-4 substituted retinoids
05/02/2003EP1305050A2 Improved oral dosage formulations
05/02/2003EP1305049A1 Methods for treating burns on mammalian skin to reduce the risk of infection and to minimize fluid loss
05/02/2003EP1305030A1 USE OF 2$g(a)-METHYL-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305016A1 Use of n-oleoylethanolamine for treating psoriasis
05/02/2003EP1305015A1 Substituted styryl benzylsulfones for treating proliferative disorders
05/02/2003EP1304992A1 Topical gel delivery system
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1119351B1 Use of catechol derivatives as proteinase inhibitors
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1035828B1 Topical compositions for regulating the oily/shiny appearance of skin
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP0973485B1 Cosmetic and dermatological agent with a hard-magnetic particle base
05/02/2003EP0967980B1 Use of aminothiazoles for treating wounds and skin
05/02/2003EP0948544B1 Monovalent antibody fragments
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0901482B1 Benzofuran carboxamides and their therapeutic use
05/02/2003EP0800584B1 Arachidonic acid and methods for the production and use thereof
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
05/02/2003CA2411011A1 5-heteroatom-substituted pyrazoles
05/02/2003CA2410466A1 Hydrazinyl and nitrogen oxide pyrazoles
05/02/2003CA2410364A1 5-heterocyclo-pyrazoles
05/01/2003WO2003035835A2 Glycoprotein compositions
05/01/2003WO2003035692A2 Modified peptides and their uses
05/01/2003WO2003035684A1 Ee3-protein family and corresponding dna sequences
05/01/2003WO2003035679A2 Molecules
05/01/2003WO2003035668A2 Novel anti-inflammatory androstane derivatives -17-carboxy-lactone substituted steroids with an aryl-carboxylic ester in position 17.alpha
05/01/2003WO2003035654A1 Phosphonic acid compounds as inhibitors of serine proteases
05/01/2003WO2003035650A1 Entry inhibitor
05/01/2003WO2003035645A1 Novel 4-(2-furoyl)aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
05/01/2003WO2003035644A1 Benzimidazole derivatives and their use as kdr protein kinase inhibitors
05/01/2003WO2003035638A1 4-imidazolin-2-one compounds
05/01/2003WO2003035635A1 6-hydroxy isoflavones, derivatives and medicaments involving same
05/01/2003WO2003035626A2 Azole derivatives and pharmaceutical compositions containing them
05/01/2003WO2003035622A1 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
05/01/2003WO2003035621A1 Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
05/01/2003WO2003035109A1 Remedies for pruritus
05/01/2003WO2003035107A1 Enzyme inhibitors for inactivating allergens
05/01/2003WO2003035090A1 Agents relieving anaphylactic allergic reactions and process for producing the same
05/01/2003WO2003035085A1 Allium sativum bulb absolutes and therapeutic or cosmetic uses
05/01/2003WO2003035079A1 A combination product comprising melagatran and dexamethasone
05/01/2003WO2003035075A1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
05/01/2003WO2003035068A1 Macrolides containing pharmaceutical compositions
05/01/2003WO2003035065A1 Benzimidazoles and analogues and their use as protein kinases inhibitors
05/01/2003WO2003035064A1 Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
05/01/2003WO2003035050A2 Use of tyrosine kinase inhibitors for promoting hair growth
05/01/2003WO2003035037A1 Solid pharmaceutical formulation for a piperazine urea derivative
05/01/2003WO2003035036A1 Montelukast granule formulation
05/01/2003WO2003035007A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
05/01/2003WO2003034987A2 Androgen receptor modulators and methods of use thereof
05/01/2003WO2003034900A2 Sterile, breathable patch for treating wound pain
05/01/2003WO2003026680A3 Method and topical formulation for treating skin conditions associated with aging
05/01/2003WO2003008412A3 Hetero-bicyclic crf antagonists
05/01/2003WO2003002109A8 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/01/2003WO2002102782A3 QUINAZOLINE DERIVATIVES which PROMOTE THE RELEASE OF PARATHYROID_HORMONE
05/01/2003WO2002100351A3 A method for treating inflammatory diseases by administering a ppar-delta agonist
05/01/2003WO2002098347A3 Methods and compositions that affect melanogenesis (pfi-016cip/pct)
05/01/2003WO2002090553A3 Recombinant fusion proteins and the trimers thereof
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002074806A3 New interferon beta-like molecules
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002067897A3 In-situ gel formation of pectins
05/01/2003WO2002060458A3 Compositions and method of tissue superoxygenation
05/01/2003WO2002049627A3 Antifungal compositions containing an antibiotic and one or more amidoamines
05/01/2003WO2002046158A9 Piperidine/piperazine-type inhibitors of p38 kinase
05/01/2003WO2002043739A3 Dermatological formulations containing clindamycin and a zinc-salt
05/01/2003WO2002030409A9 Methods for the treatment of a traumatic central nervous system injury
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003WO2002005830A3 Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof
05/01/2003WO2002000244A3 Protein mixtures for wound healing
05/01/2003US20030083610 Compositions and method of tissue superoxygenation
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083381 Comprises 5,6,7-tirnor-4,8-inter-m-phenylene prostaglandin receptor ligand/derivative; side effect reduction
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083344 Tryptase inhibitors
05/01/2003US20030083343 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
05/01/2003US20030083333 1,4-Disubstituted benzo-fused compounds
05/01/2003US20030083332 N-heterocyclic derivatives as NOS inhibitors
05/01/2003US20030083323 Oral use of dehydroepiandrosterone and some of its derivatives as pigmentation regulators
05/01/2003US20030083322 For androgenic alopecia or hirsutism; physiologically tolerated film-forming agent and solvent, a plasticizer and compound such as 4-(5-methyl-2,4-dioxo-5-trifluoromethyl)-oxazolidin-3-yl)-2 -(trifluoromethyl)-benzonitrile
05/01/2003US20030083272 Sense mrna therapy
05/01/2003US20030083265 TGF-beta inhibitors and methods
05/01/2003US20030083258 Modulation of leukocyte-endothelial interactions following ischemia
05/01/2003US20030083256 Compositions and methods for enhancing drug delivery across and into epithelial tissues
05/01/2003US20030083254 Heparanase-like proteins and nucleotides that encode them
05/01/2003US20030083246 Methods for treating rheumatic diseases using a soluble CTLA4 molecule
05/01/2003US20030083239 Hexapeptide capable of inhibiting beta-chemokine from binding to CCR3 receptor; for treating subject with a disease associated with aberrant leukocyte recruitment and/or activation
05/01/2003US20030082769 Human papillomavirus E2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor binding pocket
05/01/2003US20030082748 Nucleotide sequences coding polypeptides for use in the treatment of leukemia, tumors, psoriasis, chronic infections, autoimmune and fibrotic disorders; wound healing agents
05/01/2003US20030082666 Therapeutic treatment for autoimmune dseases; obtain hyperacetylation agent, administer to mammal, monitor adjustment in acetylation, amplified acetylation indicates treatment for autoimmune diseases
05/01/2003US20030082643 Human monoclonal antibodies to FC alpha receptor (CD89)
05/01/2003US20030082554 Nucleotide sequences coding polypeptide for use in the treatment of immunlological, thyroid, metabolic, bone and pancreatic disorders
05/01/2003US20030082225 Sterile, breathable patch for treating wound pain
05/01/2003US20030082223 Mixture contains flow control agent and thickener
1 ... 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 ... 1065